Comparison of SM cohorts and prevalence of HαT in published studies
| Study . | Sample (n) . | Population type . | Age, y, median (range) . | Sex (M) . | BST, median (IQR) . | BST (min-max) . | HαT prevalence (%) . |
|---|---|---|---|---|---|---|---|
| Current study | 76 | Non-AdvSM/AdvSM | 49 (35-59.5)∗ | 65.8% | 18.9 (13.1-34.5) | 6.7-171.8 | 6.6 |
| Lyons et al39 | 82 | Non-AdvSM | 47 (21-64)∗ | 45.1% | 38.8 (28.6-67.5) | 8.1-487 | 12.2 |
| Sordi et al37 | 444 | CM/MMAS/non-AdvSM/AdvSM | 51 (40-64)∗ | 55.2% | 25.5 (14.6-52.8) | NA | 13.3 |
| Polivka et al42 | 583 | CM/MMAS/non-AdvSM/AdvSM/MCS | 38 (0-85) | 46.0% | 62.6 (NA) | 1.4-1240 | 13.6 |
| Greiner et al (main study)40 | 180 | CM/non-AdvSM/AdvSM | 48 (11-91) | 45.6% | 36.6 (NA) | 1.8-1617 | 17.2 |
| Chovanec et al30 | 119 | DCM/MMAS/non-AdvSM | NA | NA | NA | NA | 17.7 |
| Gonzalez-de-Olano et al43 | 464 | CM/non-AdvSM/AdvSM | NA (17-83) | 57.5% | 33.6 (NA) | 2.9-1360 | 18.1 |
| Chollet et al41 | 49 | CM/non-AdvSM/AdvSM | NA (23-75) | 22.4% | NA | NA | 18.4 |
| Greiner et al (validation cohort)40 | 61 | Non-AdvSM | 49 (23-71) | 42.6% | 39.0 (NA) | 6.6-163.0 | 21.3 |
| Study . | Sample (n) . | Population type . | Age, y, median (range) . | Sex (M) . | BST, median (IQR) . | BST (min-max) . | HαT prevalence (%) . |
|---|---|---|---|---|---|---|---|
| Current study | 76 | Non-AdvSM/AdvSM | 49 (35-59.5)∗ | 65.8% | 18.9 (13.1-34.5) | 6.7-171.8 | 6.6 |
| Lyons et al39 | 82 | Non-AdvSM | 47 (21-64)∗ | 45.1% | 38.8 (28.6-67.5) | 8.1-487 | 12.2 |
| Sordi et al37 | 444 | CM/MMAS/non-AdvSM/AdvSM | 51 (40-64)∗ | 55.2% | 25.5 (14.6-52.8) | NA | 13.3 |
| Polivka et al42 | 583 | CM/MMAS/non-AdvSM/AdvSM/MCS | 38 (0-85) | 46.0% | 62.6 (NA) | 1.4-1240 | 13.6 |
| Greiner et al (main study)40 | 180 | CM/non-AdvSM/AdvSM | 48 (11-91) | 45.6% | 36.6 (NA) | 1.8-1617 | 17.2 |
| Chovanec et al30 | 119 | DCM/MMAS/non-AdvSM | NA | NA | NA | NA | 17.7 |
| Gonzalez-de-Olano et al43 | 464 | CM/non-AdvSM/AdvSM | NA (17-83) | 57.5% | 33.6 (NA) | 2.9-1360 | 18.1 |
| Chollet et al41 | 49 | CM/non-AdvSM/AdvSM | NA (23-75) | 22.4% | NA | NA | 18.4 |
| Greiner et al (validation cohort)40 | 61 | Non-AdvSM | 49 (23-71) | 42.6% | 39.0 (NA) | 6.6-163.0 | 21.3 |
AdvSM, advanced SM; IQR, interquartile range; M, male; max, maximum; MCS, mast cell sarcoma; min, minimum; NA, not available.
Range refers to IQR, 25th and 75th percentile, if available. Otherwise, min and max are included in range. AdvSM subtypes include aggressive SM, SM with an associated hematologic neoplasm, and mast cell leukemia. Nonadvanced SM (non-AdvSM) subtypes include BM mastocytosis, presumed ISM, ISM, WDSM, and SSM.